Item 8.01 Other Events.
Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it
anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), dated as of May 31, 2026, by and among the Company, Avenzo Therapeutics, Inc. and Farmington Merger Sub,
Inc., will close following the close of trading on November 20, 2026. The Company received approval from the Listing Qualifications department of The Nasdaq Stock Market to list its common stock on the Nasdaq Capital Market in connection with
the Merger.
The Company also announced updates about its previously announced special cash distribution of $13.90 per share (the “Cash
Distribution”). The Cash Distribution will continue to be payable in cash to stockholders and pre-funded warrant holders of record as of November 5, 2026 (the “Distribution Record
Date”), subject to the Nasdaq due bill procedures described below, then based on their holdings as of the Distribution Record Date and during the Due Bill Period (as defined below). The actual distribution of the amount of the Cash
Distribution will be deposited with the Company’s transfer agent on November 19, 2026 and the Company’s transfer agent is expected to commence distribution of the Cash Distribution on November 30, 2026 (the “Distribution
Payment Date”) to stockholders and pre-funded warrant holders as of the Distribution Record Date and during the Due Bill Period, with payments expected to be received by such stockholders and warrant
holders within a few days following the Distribution Payment Date.
As previously described, because the Cash Distribution per share exceeds 25% of the
Company’s stock price on the declaration date, Nasdaq has advised the Company that its common stock will trade with due bills from the Distribution Record Date through the closing of trading on November 20, 2026 (the “Due Bill
Period”), which is the last day of trading before the November 23, 2026 expected ex-dividend date for the Cash Distribution. Due bills obligate sellers of the Company’s common stock to deliver
the Cash Distribution to the buyer of such common stock during the Due Bill Period. This means that persons who purchase the Company’s common stock during the Due Bill Period (even if the trade will settle after the Due Bill Period) are
entitled to receive the Cash Distribution, and persons who sell the stock during the Due Bill Period (even if the trade will settle after the Due Bill Period) are not entitled to the Cash Distribution. Accordingly, if an investor wishes to receive
the Cash Distribution, the investor will need to hold the securities through and including the closing of trading on November 20, 2026. The due bill obligations are settled customarily between the brokers representing the buyers and sellers of
the stock. Buyers and sellers of the Company’s common stock should consult with their broker before trading to ensure they understand the effect of Nasdaq’s due bill procedures. The Company has no obligations for either the amount of the
due bill or the processing of the due bill. The timing and amount of the Cash Distribution will not be impacted by the reverse stock split of the Company’s outstanding shares of common stock that was previously announced by the Company and
expected to take effect at 4:01 p.m. Eastern Time on November 20, 2026.
In addition, the distribution of contingent value rights to holders of
record of the Company’s common stock, pre-funded warrants, restricted stock units and In the Money Parent Options (as defined in the Merger Agreement) as of the Distribution Record Date is expected to
occur on November 23, 2026, one business day following the closing of the transactions contemplated by the Merger Agreement.
Forward-Looking
Statements
This Current Report on Form 8-K and the exhibits filed or furnished herewith contain
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the implementation and expected timing of the reverse stock
split; the expected distribution of the Cash Distribution; the expected commencement of trading on a split-adjusted basis; the anticipated completion and timing of the Merger; the procedures for the Due Bill Period; and Avenzo’s and the
Company’s plans to develop and commercialize therapies and the potential of their product candidates. The words “may,” “believes,” “expects,” “anticipates,” “intends,”
“plans,” “forecasts,” “estimates,” “will,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these
words. These statements are based on management’s current expectations, estimates, beliefs and assumptions and are subject to risks and uncertainties that could cause actual results or the timing of events to differ materially from those
expressed or implied.
These risks and uncertainties include, among others, the risk that the Merger will be delayed or will not be completed because
closing conditions are not satisfied or waived, including conditions related to Nasdaq listing approvals; the occurrence of events or circumstances that could give rise to termination of the Merger Agreement; delays in implementing the reverse stock
split or commencing split-adjusted trading; the risk that the reverse stock split will not result in a sustained increase in the trading price of the common stock or ensure compliance with Nasdaq listing requirements; risks associated with the
development and commercialization of product candidates;